ASCO 2017 | Dabrafenib and trametinib: a promising combination for the treatment of melanoma

Dirk Schadendorf

Dirk Schadendorf, MD, from the West German Cancer Centre, University Hospital Essen, Essen, Germany, talks to us about the COMBI-v trial, a Phase III study comparing dabrafenib and trametinib combination therapy with vemurafenib monotherapy on treating patients with BRAF Val600-mutation-positive melanoma (NCT01597908). As explained by Prof. Schadendorf, it was found that the combination regimen showed greater efficacy in terms of response rates, overall survival and tumour control compared to monotherapy, which suggests that this regimen may represent potential treatment for melanoma. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

Share this video  
Similar topics